

DRUG TESTING: TECHNOLOGIES AND GLOBAL MARKETS



PHM013F
March 2015

Jon Evans
Project Analyst

ISBN: 1-62296-056-4



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOAL AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	2
SCOPE OF REPORT	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 EXECUTIVE SUMMARY	6
<i>SUMMARY TABLE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 DRUGS OF ABUSE TESTING PRACTICES	9
SINGLE- VS MULTI-PARAMETER TEST	9
DOA SCREENING	9
CONFIRMATION TESTING	10
URINE TESTS	10
OTHER TESTING METHODS	11
BLOOD TESTING	11
ORAL FLUID TESTING	11
SALIVA TESTING	12
SWEAT TESTING	12
HAIR TESTING	12
TESTING LOCATIONS	12
LABORATORY-BASED DAT	12
Criminal Justice	13
Police	14
Prisons	14
Probation	14
Workplace Screening	14
Others	15
Military	15
Customs and Excise	15
Education	15
POINT OF CARE (POC) DATS	15
<i>TABLE 1 ADVANTAGES AND DISADVANTAGES OF POINT OF CARE TESTING</i>	16
ONSITE TESTING VS LABORATORY TESTING	16
<i>TABLE 2 MAJOR ADVANTAGES AND DISADVANTAGES OF ONSITE TESTING</i>	16
SAMPLE TYPES FOR LABORATORY TESTING	17
URINE TESTING	17

TOPIC	PAGE NO.
HAIR TESTING	17
SALIVA/ORAL FLUID TESTING	18
BLOOD TESTING	18
SWEAT TESTING	18
EYE REFLEX	19
DETECTION PERIOD	19
<i>TABLE 3 DETECTION PERIODS FOR VARIOUS TYPES OF DRUG TESTING</i>	19
FOOLING A DRUG TEST	20
FOOLING URINE TESTING	20
<i>TABLE 4 COMMON PARAMETERS TESTED FOR URINE SPECIMEN VALIDITY</i>	21
<i>TABLE 5 SOME OF THE COMMERCIAL/Common ADULTERANTS USED IN FOOLING URINE TESTS AND THEIR EFFECTS</i>	22
FOOLING HAIR TESTING	23
FOOLING SALIVA TESTING	23
SAMPLE VALIDITY TESTS	23
<i>TABLE 6 URINE SAMPLE VALIDITY TEST METHODS</i>	24
FALSE POSITIVES AND FALSE NEGATIVES	25
FALSE POSITIVES	25
<i>TABLE 7 CROSS REACTANTS THAT CAN LEAD TO FALSE POSITIVES IN DOA TESTING</i>	26
FALSE NEGATIVES	26
TESTING TECHNOLOGIES	27
IMMUNOASSAYS	27
ENZYME IMMUNOASSAY (EIA)	28
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)	28
ENZYME MULTIPLIED IMMUNOASSAY TECHNOLOGY (EMIT)	28
FLUORESCENCE POLARIZATION IMMUNOASSAY (FPIA)	29
RADIOIMMUNOASSAY (RIA)	29
CHROMATOGRAPHY	29
Gas Chromatography (GC)	29
High Performance Liquid Chromatography (HPLC)	29
Thin-Layer Chromatography (TLC)	30
Mass Spectrometry (MS)	30
Capillary Electrophoresis (CE)	30
Hyphenated MS/Chromatography	31
Gas-Chromatography-Mass Spectrometry (GC/MS)	31
EYE REFLEX MEASUREMENTS	31
CHAPTER 4 GOVERNMENT REGULATIONS: DRUG TRAFFICKING AND DRUG ABUSE TESTING	33
NORTH AMERICA	33
NATIONAL LEGISLATION AND POLICY	33
Canada	33
Drug Free Workplace	33
Mexico	33
The United States	34
Drug-Free Workplace	34
<i>TABLE 8 U.S. DRUG TESTING LEGISLATIONS BY STATE, 2014</i>	36
U.S. Department of Transportation	41

TOPIC	PAGE NO.
Drug Testing in the Military	42
Public Assistance Qualifications	42
Drug Testing for Individuals Convicted of Drug Felonies	42
2014 Legislation	42
Legislative Proposals:	42
Legislative Enactments:	42
Quick Facts	43
2013 Legislation	43
Legislative Proposals:	43
Legislative Enactments:	43
2012 Legislation	44
Programs Included	45
2011 Legislation	45
SOUTH AMERICA	46
NATIONAL LEGISLATION AND POLICY	46
Bolivia	46
Brazil	47
Drug-Free Workplace	47
Colombia	47
Ecuador	47
Guyana	48
Paraguay	48
Peru	48
CENTRAL AMERICA AND THE CARIBBEAN	49
NATIONAL LEGISLATION AND POLICY	49
Costa Rica	49
Cuba	49
El Salvador	49
Guatemala	49
Haiti	50
Jamaica	50
Nicaragua	50
Panama	50
Tegucigalpa	50
The Bahamas	51
The Netherlands Antilles	51
Trinidad and Tobago	51
EUROPE	51
NATIONAL LEGISLATION AND POLICY	52
Bosnia and Herzegovina	52
Denmark	52
France	52
Germany	53
Italy	53
Latvia	53
Norway	53
Romania	53

TOPIC	PAGE NO.
Sweden	54
Switzerland	54
The Netherlands	54
The United Kingdom	55
DRUG-FREE WORKPLACE POLICY AND LEGISLATION BY EUROPEAN COUNTRY	55
<i>TABLE 9 DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008*</i>	55
ASIA-PACIFIC	60
NATIONAL LEGISLATION AND POLICY	60
Australia	60
Bangladesh	60
Bhutan	61
Cambodia	61
Hong Kong	61
India	61
The NDPS (Regulation of Controlled Substances) Order, 1993	62
Japan	62
Maldives	63
Myanmar	63
Nepal	63
New Zealand	64
Singapore	64
South Korea	65
Sri Lanka	65
Taiwan	66
Thailand	66
Vietnam	66
CHAPTER 5 OVERVIEW	68
DRUG ABUSE TESTING	68
INTRODUCTION	68
INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY DRUG TYPE	68
<i>TABLE 10 NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003-2007 (MILLIONS)</i>	68
Amphetamine-Type Stimulants Market	69
Cannabis Market	69
Coca/Cocaine Market	70
Opium/Heroin Market	70
INTERNATIONAL DRUG TRAFFICKING AND ILLICIT DRUG USE TRENDS BY GEOGRAPHIC REGION	70
Africa	70
Central America and Caribbean	71
North America	71
<i>TABLE 11 NORTH AMERICAN DOA SEIZURES, 2012</i>	72
South America	76
East and Southeast Asia	77
South Asia	77
West Asia	77

TOPIC	PAGE NO.
Europe	78
TABLE 12 ANNUAL PREVALENCE OF OPIOID USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	78
TABLE 13 ANNUAL PREVALENCE OF COCAINE USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	79
TABLE 14 ANNUAL PREVALENCE OF CANNABIS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	80
TABLE 15 ANNUAL PREVALENCE OF ATS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	81
TABLE 16 ANNUAL PREVALENCE OF ECSTASY USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	82
Oceania	83
U.S. DRUGS OF ABUSE STATISTICS	83
National Household Survey on Drug Abuse: SAMHSA U.S.	83
Survey by Drug Type	83
TABLE 17 DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12 YRS AND OLDER), 2011 AND 2012 (THOUSANDS)	83
Survey by Age	84
TABLE 18 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY AGE, 2011 AND 2012 (THOUSANDS)	84
TABLE 19 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, RACE, AND ETHNICITY, 2011 AND 2012 (THOUSANDS)	85
Survey by Education and Current Employment Status	86
TABLE 20 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER BY GENDER, RACE, EDUCATION AND EMPLOYMENT, 2011 AND 2012 (THOUSANDS)	86
CHAPTER 6 GLOBAL DRUGS OF ABUSE TESTING MARKET BY SAMPLE MATRIX	89
DRUGS OF ABUSE TESTING SALES	89
TABLE 21 GLOBAL SALES CONTRIBUTION FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (%)	89
TABLE 22 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (\$ MILLIONS)	90
FIGURE 1 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2013-2019 (\$ MILLIONS)	90
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY URINE	90
TABLE 23 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2019 (\$ MILLIONS)	91
FIGURE 2 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2013-2019 (\$ MILLIONS)	91
TABLE 24 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 (\$ MILLIONS)	92
FIGURE 3 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2014 (%)	92
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY BLOOD	92
TABLE 25 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2019 (\$ MILLIONS)	93
FIGURE 4 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2013-2019 (\$ MILLIONS)	93
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY ORAL FLUID	93
TABLE 26 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2019 (\$ MILLIONS)	94

TOPIC	PAGE NO.
<i>FIGURE 5 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2013-2019 (\$ MILLIONS)</i>	94
<i>TABLE 27 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 (\$ MILLIONS)</i>	94
<i>FIGURE 6 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2014 (%)</i>	95
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY HAIR	95
<i>TABLE 28 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2019 (\$ MILLIONS)</i>	95
<i>FIGURE 7 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2013-2019 (\$ MILLIONS)</i>	96
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY SWEAT	96
<i>TABLE 29 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2019 (\$ MILLIONS)</i>	96
<i>FIGURE 8 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2013-2019 (\$ MILLIONS)</i>	96
GLOBAL SALES OF DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES	97
<i>TABLE 30 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2019 (\$ MILLIONS)</i>	97
<i>FIGURE 9 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2013-2019 (\$ MILLIONS)</i>	97
CHAPTER 7 WORLDWIDE INDUSTRY STRUCTURE	100
REGIONAL ANALYSIS	100
<i>FIGURE 10 DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGION, 2014 (%)</i>	100
TOTAL DOA TESTING AND DRUG MONITORING MARKETS AND FORECASTS	101
<i>TABLE 31 GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	101
GROWTH TRENDS-LABORATORY-BASED AND ONSITE DOA TESTING MARKETS	101
LABORATORY-BASED DOA TESTING MARKETS AND FORECASTS	101
<i>TABLE 32 DRUGS OF ABUSE TESTING MARKET FORECAST FOR LABORATORY-BASED TESTING, THROUGH 2019 (\$ MILLIONS)</i>	101
ONSITE DOA TESTING MARKETS AND FORECASTS	102
<i>TABLE 33 DRUGS OF ABUSE TESTING MARKET FORCAST FOR ONSITE TESTING, THROUGH 2019 (\$ MILLIONS)</i>	102
COMPETITIVE ANALYSIS	102
<i>TABLE 34 MOST NOTABLE MERGERS AND ACQUISITIONS IN THE DOA TESTING MARKETS, 2000-2012</i>	102
KEY MARKET PLAYERS IN THE DOA TESTING MARKETS AND THEIR PRODUCTS	103
<i>TABLE 35 MAJOR COMPANIES AND THEIR PRODUCTS IN THE DOA TESTING MARKET</i>	103
LABORATORY-BASED DOA TESTING MARKET SEGMENT	104
<i>TABLE 36 COMPANIES OFFERING LABORATORY-BASED DOA TESTING PRODUCTS</i>	104
ONSITE TESTING MARKET SEGMENT FOR DOA	106
<i>TABLE 37 MAIN ONSITE DOA TESTING MARKET PLAYERS AND THEIR PRODUCTS</i>	106
COMMON DRUGS OF ABUSE AND MOST POPULAR DEVICES USED FOR TESTING THEM	107
<i>TABLE 38 COMMON DOA AND POPULAR URINE DRUG SCREENING PRODUCTS</i>	107
COMPANIES IN THE ORAL FLUID, HAIR, AND SWEAT TESTING SEGMENTS FOR DOA	109

TOPIC	PAGE NO.
<i>TABLE 39 KEY MARKET PLAYERS OFFERING DOA TESTING PRODUCTS ON ORAL FLUID, HAIR AND SWEAT SAMPLE MATRICES</i>	109
CHAPTER 8 PATENT ANALYSIS	111
<i>TABLE 40 U.S. DRUGS OF ABUSE TESTING PATENTS BY PATENT NUMBER AND TITLE, 2007-2014</i>	111
<i>TABLE 41 U.S. DRUGS OF ABUSE TESTING PATENTS BY ASSIGNEE, 1978-2007</i>	112
CHAPTER 9 COMPANY PROFILES	119
ABBOTT LABORATORIES	119
ACON LABORATORIES INC.	120
AGILENT TECHNOLOGIES	120
ALERE INC.	121
AMERICAN BIO MEDICA CORP. (ABMC)	122
BECKMAN COULTER	122
BIO-RAD LABORATORIES, INC	123
CONCATENO, PLC	124
ELITECH GROUP	124
F. HOFFMANN-LA ROCHE LTD.	125
MEDTOX DIAGNOSTICS	125
MICROGENICS	126
NANOGEN INC.	126
OLYMPUS DIAGNOSTICS SYSTEMS	127
ORASURE TECHNOLOGIES INC.	127
ORTHO-CLINICAL DIAGNOSTICS	128
SIEMENS HEALTHCARE DIAGNOSTICS INC.	129
CHAPTER 10 APPENDIX A	131
<i>TABLE 42 GLOSSARY OF COMMON TERMS</i>	131
<i>TABLE 43 GLOSSARY OF SCIENTIFIC ABBREVIATIONS</i>	136
<i>TABLE 44 ASSOCIATIONS</i>	136
CHAPTER 11 APPENDIX B	139
<i>TABLE 45 DOA SEIZURES IN EUROPE, 2012</i>	139

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 ADVANTAGES AND DISADVANTAGES OF POINT OF CARE TESTING	16
TABLE 2 MAJOR ADVANTAGES AND DISADVANTAGES OF ONSITE TESTING	16
TABLE 3 DETECTION PERIODS FOR VARIOUS TYPES OF DRUG TESTING	19
TABLE 4 COMMON PARAMETERS TESTED FOR URINE SPECIMEN VALIDITY	21
TABLE 5 SOME OF THE COMMERCIAL/Common ADULTERANTS USED IN FOOLING URINE TESTS AND THEIR EFFECTS	22
TABLE 6 URINE SAMPLE VALIDITY TEST METHODS	24
TABLE 7 CROSS REACTANTS THAT CAN LEAD TO FALSE POSITIVES IN DOA TESTING	26
TABLE 8 U.S. DRUG TESTING LEGISLATIONS BY STATE, 2014	36
TABLE 9 DRUG-TESTING LEGISLATION BY EUROPEAN COUNTRY, 2008*	55
TABLE 10 NUMBER OF ILLICIT DRUG USERS GLOBALLY, 2003-2007 (MILLIONS)	68
TABLE 11 NORTH AMERICAN DOA SEIZURES, 2012	72
TABLE 12 ANNUAL PREVALENCE OF OPIOID USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	78
TABLE 13 ANNUAL PREVALENCE OF COCAINE USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	79
TABLE 14 ANNUAL PREVALENCE OF CANNABIS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	80
TABLE 15 ANNUAL PREVALENCE OF ATS USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	81
TABLE 16 ANNUAL PREVALENCE OF ECSTASY USE AS A PERCENTAGE OF THE POPULATION AGED 15-64 BY MOST RECENT DATA YEAR	82
TABLE 17 DRUG ABUSE STATISTICS IN THE U.S. BY DRUG TYPE (12 YRS AND OLDER), 2011 AND 2012 (THOUSANDS)	83
TABLE 18 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY AGE, 2011 AND 2012 (THOUSANDS)	84
TABLE 19 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS 12 YRS AND OLDER IN THE U.S. BY GENDER, RACE, AND ETHNICITY, 2011 AND 2012 (THOUSANDS)	85
TABLE 20 ILLICIT DRUG USE IN LIFETIME AMONG PERSONS AGED 12 OR OLDER BY GENDER, RACE, EDUCATION AND EMPLOYMENT, 2011 AND 2012 (THOUSANDS)	86
TABLE 21 GLOBAL SALES CONTRIBUTION FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (%)	89
TABLE 22 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, THROUGH 2019 (\$ MILLIONS)	90
TABLE 23 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, THROUGH 2019 (\$ MILLIONS)	91
TABLE 24 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 (\$ MILLIONS)	92
TABLE 25 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, THROUGH 2019 (\$ MILLIONS)	93
TABLE 26 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, THROUGH 2019 (\$ MILLIONS)	94
TABLE 27 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID: LABORATORY BASED VERSUS ONSITE, THROUGH 2019 (\$ MILLIONS)	94
TABLE 28 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, THROUGH 2019 (\$ MILLIONS)	95
TABLE 29 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, THROUGH 2019 (\$ MILLIONS)	96

TABLE HEADING	PAGE NO.
TABLE 30 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, THROUGH 2019 (\$ MILLIONS)	97
TABLE 31 GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY REGION, THROUGH 2019 (\$ MILLIONS)	101
TABLE 32 DRUGS OF ABUSE TESTING MARKET FORECAST FOR LABORATORY-BASED TESTING, THROUGH 2019 (\$ MILLIONS)	101
TABLE 33 DRUGS OF ABUSE TESTING MARKET FORECAST FOR ONSITE TESTING, THROUGH 2019 (\$ MILLIONS)	102
TABLE 34 MOST NOTABLE MERGERS AND ACQUISITIONS IN THE DOA TESTING MARKETS, 2000-2012	102
TABLE 35 MAJOR COMPANIES AND THEIR PRODUCTS IN THE DOA TESTING MARKET	103
TABLE 36 COMPANIES OFFERING LABORATORY-BASED DOA TESTING PRODUCTS	104
TABLE 37 MAIN ONSITE DOA TESTING MARKET PLAYERS AND THEIR PRODUCTS	106
TABLE 38 COMMON DOA AND POPULAR URINE DRUG SCREENING PRODUCTS	107
TABLE 39 KEY MARKET PLAYERS OFFERING DOA TESTING PRODUCTS ON ORAL FLUID, HAIR AND SWEAT SAMPLE MATRICES	109
TABLE 40 U.S. DRUGS OF ABUSE TESTING PATENTS BY PATENT NUMBER AND TITLE, 2007-2014	111
TABLE 41 U.S. DRUGS OF ABUSE TESTING PATENTS BY ASSIGNEE, 1978-2007	112
TABLE 42 GLOSSARY OF COMMON TERMS	131
TABLE 43 GLOSSARY OF SCIENTIFIC ABBREVIATIONS	136
TABLE 44 ASSOCIATIONS	136
TABLE 45 DOA SEIZURES IN EUROPE, 2012	139

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL DRUGS OF ABUSE TESTING MARKET FORECAST BY TEST MATRIX, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SAMPLE MATRIX, 2013-2019 (\$ MILLIONS)	90
FIGURE 2 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE, 2013-2019 (\$ MILLIONS)	91
FIGURE 3 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY URINE: LABORATORY BASED VERSUS ONSITE, 2014 (%)	92
FIGURE 4 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY BLOOD, 2013-2019 (\$ MILLIONS)	93
FIGURE 5 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL FLUID, 2013-2019 (\$ MILLIONS)	94
FIGURE 6 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY ORAL: LABORATORY BASED VERSUS ONSITE, 2014 (%)	95
FIGURE 7 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY HAIR, 2013-2019 (\$ MILLIONS)	96
FIGURE 8 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY SWEAT, 2013-2019 (\$ MILLIONS)	96
FIGURE 9 GLOBAL SALES FORECAST FOR DRUGS OF ABUSE TESTING BY OTHER SAMPLE MATRICES, 2013-2019 (\$ MILLIONS)	97
FIGURE 10 DRUGS OF ABUSE TESTING MARKETS BY GEOGRAPHIC REGION, 2014 (%)	100